Skip to main content
Premium Trial:

Request an Annual Quote

Burnham Institute Licenses HuCAL GOLD Antibodies From Morphosys

NEW YORK (GenomeWeb News) — The Burnham Institute will use Morphosys’ HuCAL GOLD-based antibodies for medical research, Morphosys said today.
 
HuCAL GOLD was developed by AbD Serotec, a MorphoSys subsidiary, and will be used to “identify and validate target molecules with potential medical implications” to help the Burnham Institute advance a number of ongoing programs.
 
MorphoSys said it will retain the commercial rights to all antibodies derived from the collaboration, and will distribute them through Serotec.  
 
Simon Moroney, MorphoSys’ CEO, called the potential access to disease-related target molecules a “key asset,” and said the contract could help both the company’s Serotec division and its long-term therapeutic business.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.